Actinogen enhances XanaMIA Phase 2b Alzheimers trial
Filed with ASX · · 3 pages · English
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Actinogen closes successful $10 million rights issue offer
- Actinogen FY2023 results, following the science
- ACW Appendix 4E and 2023 Annual Report
- ACW secures further $0.5m rights issue shortfall commitment
- ACW secures shortfall commitments of $4.56m for rights issue
Later from Actinogen Medical
- Actinogen September quarterly activity report & Appendix 4C
- Actinogen receives $4.8 million R&D tax incentive rebate
- ACW December 2023 quarterly activity report & Appendix 4C
- Actinogen awarded UK Innovation Passport for Xanamem
- Response to ASX Aware Query
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical